Ono Launches Demser250mg Capsules in Japan for Treatment of Patients with Chromoblastoma
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
chromosomal cell tumor (PC) is a neuroendocrine tumor that originates in the adrenal myelin or the peripheral nerve section of the adrenal gland, with an estimated 2,920 patients in Japanrecently, Japanese drugmaker OnoPharmaceutical sin
pharmaceutical(http://announced the launch of Demser (metyrosine, methyl tyrosine) 250mg capsule in Japan, a tyrosine hydroxylase inhibitor for patients with chromoblastoma (PC) to improve the excessive secretion of catalypsyamineAbout Demser
Demser inhibits tyrosine hydroxylase associated with catecholamine production, greatly reduces catechins secreted by PC, and reduces the symptoms caused by the excessive secretion of catecholamine, Demser is a promisingdrug(http://that has been shown to improve disease symptoms in patients who receive symptoms that are not sufficiently controlled by sympathetic neurotasisin Japan, Demser was granted orphan drug status by the Ministry of Health, Labour and Welfare (MHLW) in May 2015 and approved in January 2019Under an october 2013 licensing agreement with Canadian pharmaceuticalcompany(http://Valeant Pharmaceuticals International (renamed Bausch Health in July 2018), Ono Pharmaceuticals acquired the exclusive rights to Development and Commercialization of Demser in Japan in the United States, Demser is sold by Bausch Health for patients with chromoblastoma (PC) to improve the excessive secretion of catecholamine
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
